An always-updating digest. Research subagents read new studies, trials, and reporting around the clock and rewrite them in clear, honest language — with sources and caveats attached.
New studies are exploring biological markers that may complement existing autism assessments, with eye-tracking patterns, microbial metabolites, and digital phenotyping showing research promise. While these approaches could expand diagnostic options, experts emphasize they remain investigational and must be validated across diverse populations.
The CDC's latest autism surveillance report finds autism prevalence among 8-year-olds has increased to 1 in 31 (3.2%), with notable gains in identification among Asian, Black, and Hispanic children. Experts attribute the rise to improved screening and reduced disparities, not a true increase in cases.
Recent studies highlight a significant gap in the diagnosis of autism among adults over 40, with estimates suggesting that 89-97% of autistic adults in this age group in the UK may be undiagnosed. This gap leads to missed opportunities for support in employment, healthcare, and aging. This article delves into the reasons behind this underdiagnosis, its impacts, and how families and professionals can better support autistic adults.
Recent advances in biomarker research—including eye-tracking, microbiome analysis, and digital phenotyping—are bringing scientists closer to earlier and more accurate autism screening tools. While these methods show significant promise, experts caution that further validation is needed before widespread clinical use.
The CDC's latest report reveals that autism prevalence among 8-year-olds in the U.S. has increased to 1 in 31, up from 1 in 36 in 2020. Notably, the data shows higher rates among Asian, Black, and Hispanic children compared to White children for the first time in this dataset, while boys continue to be diagnosed more frequently than girls.
Recent studies reveal significant gaps in identifying and supporting autistic adults over 40, with UK estimates suggesting 89-97% may not have received formal diagnoses. This systemic oversight exacerbates employment challenges and healthcare disparities, particularly for those navigating aging without accommodations. The article explores both structural barriers and community-driven solutions.
Recent studies highlight promising biomarker-based approaches for early autism detection, including urinary metabolites linked to gut microbes, eye-tracking in primary care, and an AI-powered stool test in pilot phase. While these tools could reduce diagnosis delays, questions remain about their broad applicability, clinical readiness, and ethical implications of earlier labeling.
The CDC's latest report reveals autism prevalence among 8-year-olds has increased to 1 in 31 (3.2%) in 2022, up from 1 in 36 in 2020. The rise reflects improved screening in minority populations and evolving diagnostic practices, not a true epidemic.
Two emerging biomarker approaches—urinary metabolites and eye-tracking—are being studied as potential supplements to current autism diagnostic methods. Peer-reviewed research highlights their promise, but emphasizes the need for broader validation and integration with clinical assessments.
The CDC's latest report reveals that autism prevalence among 8-year-olds in the U.S. has risen to 1 in 31 (3.2%), up from 1 in 36 (2.8%) in 2020. The findings highlight significant demographic and geographic variations, as well as persistent disparities in early diagnosis.
A significant majority of autistic adults over 40 in the UK remain undiagnosed, leading to missed support opportunities and heightened risks in employment, mental health, and healthcare access. Workplace accommodations can help, but without diagnosis, many are left without the tools they need.
Recent advances in eye-tracking and microbial biomarkers are offering new hope for earlier autism diagnosis, potentially supplementing current behavioral assessments. While eye-tracking has strong evidentiary support, microbial tests face skepticism due to unvalidated claims and confounding factors.
